Business Context and Reporting Period
Company: Stoke Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 30, 2026
Principal Business: Biopharmaceutical company developing zorevunersen, a potential disease-modifying treatment for Dravet syndrome.
Key Financial Metrics
This filing is a current report regarding a material corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Corporate Events
- Study Enrollment Complete: The Company completed enrollment of 162 patients into the Phase 3 EMPEROR study of zorevunersen.
- Geographic Scope: Enrollment was conducted across the U.S., U.K., and Japan.
- Primary Endpoint Status: Approximately 50 patients have reached the 28-week treatment mark, which is the time point for measuring the primary endpoint (change in major motor seizure frequency).
Guidance, Outlook, and Management Commentary
- Data Readout: A Phase 3 data readout from the enrolled patients is anticipated in the third quarter of 2027.
- Regulatory Timeline:
- Initiation of a rolling New Drug Application (NDA) to the U.S. FDA is planned for the first quarter of 2027.
- Completion of the NDA submission is expected in the second half of 2027.
Investor Verification Checklist
- Verify the specific inclusion/exclusion criteria for the 162 enrolled patients in the EMPEROR study.
- Confirm the exact timeline for the 28-week data readout relative to the Q3 2027 guidance.
- Review the attached Press Release (Exhibit 99.1) for details on the rolling NDA submission strategy.
- Monitor subsequent filings for updates on patient retention and safety data as the 28-week milestone is reached.